Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations

Basic and Clinical Pharmacology and Toxicology

Volumn 98, Issue 6, 2006, Pages 559-564

  Barbosa Jr , Fernando ^a   Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; LEAD; MATRIX METALLOPROTEINASE;

ADULT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CARDIOVASCULAR DISEASE; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FEMALE; HUMAN; LEAD BLOOD LEVEL; LEAD POISONING; MALE; MASS SPECTROMETRY; NEOPLASM; NORMAL HUMAN; PRIORITY JOURNAL; PROGNOSIS; ZYMOGRAPHY;

ADOLESCENT; ADULT; DEMOGRAPHY; ENZYME PRECURSORS; FEMALE; HUMANS; LEAD; LEAD POISONING; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED;

EID: 33646754539     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_392.x     Document Type: Article

References (32)

1. Altieri P. C. Brunelli S. Garibaldi A. Nicolino S. Ubaldi P. Spallarossa L. Olivotti P. Rossettin A. Barsotti G. Ghigliotti. : Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur. J. Clin. Invest. 2003, 33, 648 656.
2. ATSDR : Toxicological profile for lead. US Department of Health and Human Services, Public Health Services, Atlanta, GA, 1999.
3. Barbosa Jr.., F. V. C. Sandrim J. A. Uzuelli R. F. Gerlach J. E. Tanus-Santos : eNOS genotype-dependent correlation between whole blood lead and plasma nitric oxide products concentrations. Nitric Oxide 2006, 14, 58 64.
4. Barbosa Jr.., F. J. E. Tanus-Santos R. F. Gerlach P. J. Parsons : Current needs and limitations on the use of biomarkers of internal dose to diagnose lead exposure. Environ. Health Perspect 2005, 113, 1669 1674.
5. Blankenberg S. H. J. Rupprecht O. Poirier C. Bickel M. Smieja G. Hafner J. Meyer F. Cambien L. Tiret : Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107, 1579 1585.
6. Demacq C. A. P. de Souza A. A. Machado R. F. Gerlach J. E. Tanus-Santos : Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin. Chim. Acta 2006, 365, 183 187.
7. Farias E. S. Ranuncolo C. Cresta S. Specterman E. Armanasco M. Varela J. Lastiri M. G. Pallotta E. Bal de Kier Joffe L. Puricelli : Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int. J. Cancer 2000, 89, 389 394.
8. Galis Z. S. J. J. Khatri : Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 2002, 90, 251 262.
9. Gerlach R. F. J. A. Uzuelli C. D. Souza-Tarla J. E. Tanus-Santos : Effect of anticoagulants on plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal. Biochem. 2005, 344, 147 149.
10. Gulson B. L. C. W. Jameson K. R. Mahaffey K. J. Mizon M. J. Korsch G. Vimpani : Pregnancy increases mobilization of lead from maternal skeleton. J. Lab. Clin. Med. 1997, 130, 51 62.
11. Gulson B. L. K. R. Mahaffey C. W. Jameson K. J. Mizon M. J. Korsch M. A. Cameron J. A. Eisman : Mobilization of lead from the skeleton during the postnatal period is larger than during pregnancy. J. Lab. Clin. Med. 1998, 131, 324 329.
12. Gulson B. L. J. G. Pounds P. Mushak B. J. Thomas B. Gray M. J. Korsch : Estimation of cumulative lead releases (lead flux) from the maternal skeleton during pregnancy and lactation. J. Lab. Clin. Med. 1999, 134, 631 640.
13. Gurer H. N. Ercal : Can antioxidants be beneficial in the treatment of lead poisoning? Free Radic. Biol. Med. 2000, 29, 927 945.
14. Kleiner D. E. W. G. Stetler-Stevenson : Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 1994, 218, 325 329.
15. Leber T. M. F. R. Balkwill : Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal. Biochem. 1997, 249, 24 28.
16. Lynch J. R. R. Blessing W. D. White H. P. Grocott M. F. Newman D. T. Laskowitz : Novel diagnostic test for acute stroke. Stroke 2004, 35, 57 63.
17. Manton W. I. S. J. Rothenberg M. Manalo : The lead content of blood serum. ©Environ. Res. 2001, 86, 263 273.
18. Moller L. T. S. Kristensen : Blood lead as a cardiovascular risk factor. Amer. J. Epidemiol. 1992, 136, 1091 1100.
19. Montenegro M. F. F. Barbosa Jr.. V. C. Sandrim R. F. Gerlach J. E. Tanus-Santos : A polymorphism in the delta-aminolevulinic acid dehydratase gene modifies plasma/whole blood lead ratio. Arch. Toxicol. 2006, in press.
20. Navas-Acien A. E. Selvin A. R. Sharrett E. Calderon-Aranda E. Silbergeld E. Guallar : Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation 2004, 109, 3196 3201.
21. Nelson K. K. J. A. Melendez : Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med. 2004, 37, 768 784.
22. Ni Z. S. Hou C. H. Barton N. D. Vaziri : Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int. 2004, 66, 2329 2336.
23. Pirkle J. L. J. Schwartz J. R. Landis W. R. Harlan : The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Amer. J. Epidemiol. 1985, 121, 246 258.
24. Ranuncolo S. M. E. Armanasco C. Cresta E. Bal De Kier Joffe L. Puricelli : Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int. J. Cancer 2003, 106, 745 751.
25. Schutz A. I. A. Bergdahl A. Ekholm S. Skerfving : Measurement by ICP-MS of lead in plasma and whole blood of lead workers and controls. Occup. Environ. Med. 1996, 53, 736 740.
26. Schwartz J. : Lead, blood pressure, and cardiovascular disease in men. Arch. Environ. Health 1995, 50, 31 37.
27. Silbergeld E. K. J. Schwartz K. Mahaffey : Lead and osteoporosis: mobilization of lead from bone in postmenopausal women. Environ. Res. 1988, 47, 79 94.
28. Souza-Tarla C. D. J. A. Uzuelli A. A. Machado R. F. Gerlach J. E. Tanus-Santos : Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin. Biochem. 2005, 38, 410 414.
29. Tayebjee M. H. G. Y. Lip A. D. Blann R. J. Macfadyen : Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb. Res. 2005, 115, 205 210.
30. Van den Steen P. E. B. Dubois I. Nelissen P. M. Rudd R. A. Dwek G. Opdenakker : Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 2002, 37, 375 536.
31. Vaziri N. D. D. A. Sica : Lead-induced hypertension: role of oxidative stress. Curr. Hypertens. Rep. 2004, 6, 314 320.
32. Zhou Y. R. A. Zanao F. Barbosa P. J. Parsons F. J. Krug : Investigations on a W-Rh permanent modifier for the detection of Pb in blood by electrothermal atomic absorption spectrometry. Spectrochim. Acta Part B. 2002, 57, 1291 1300.